Why Opt In Is Not Enough Under DPDP Act in Pharma?
The Digital Personal Data Protection Act 2023 (DPDP Act) ends that assumption.
Under the DPDP Act, opt-in alone no longer meets the legal standard for consent. What once worked as a practical shortcut now creates real compliance risk for pharma and healthcare organisations running digital engagement programs at scale.
This article explains why opt-in is not enough under the DPDP Act, where legacy consent practices break down, and how pharma marketing teams must redesign consent to stay compliant — without slowing growth.
Why Is Opt-In Not Enough Under DPDP?
Opt-in is not enough under DPDP because it does not meet the requirements of explicit, informed, and purpose-specific consent.
• Opt-in lacks purpose clarity
• Opt-in does not define communication channels
• Opt-in is often not time-bound
• Opt-in is difficult to audit
How Opt In Became the Default in Pharma Marketing ?
Opt in evolved as a convenience driven model.
Doctors opted in during conferences, CME registrations, website sign ups, or field force interactions. Patients opted in to programs or digital platforms. Once captured, this consent was assumed to be broad and enduring.
Marketing systems were built around this assumption. CRMs stored a single consent flag. Campaign tools treated opt in as universal permission. Teams focused on reach rather than scope.
This worked largely because regulatory expectations were unclear and enforcement was limited.
DPDP changes that environment.
What DPDP Requires Beyond Opt In ?
DPDP introduces a stricter definition of valid consent.
Consent must be explicit, informed, and specific to a defined purpose. Individuals must understand what data is being used, how it will be used, and why. Consent must also be capable of being withdrawn easily.
To understand how explicit consent works in practice, read our guide on capturing explicit consent at scale.
Explicit consent in pharma under DPDP requires clear definition of purpose, communication channel, and data usage.
Opt in models rarely meet these criteria. They often lack purpose clarity, channel specificity, and withdrawal mechanisms.
Under DPDP, these gaps matter.
Purpose Specificity Is the Core Gap
The biggest reason opt in fails under DPDP is lack of purpose specificity.
Many opt ins simply state that the individual agrees to receive communication. They do not distinguish between scientific education, promotional content, surveys, or analytics.
DPDP requires consent to be tied to a clear purpose. Using data beyond that purpose without renewed consent is non compliant.
This also relates to purpose limitation under DPDP, where data cannot be reused beyond consented use.
Marketing teams that reuse opt in consent across different campaign types expose themselves to risk.
Channel Blind Consent No Longer Works
Opt in consent often ignores channel distinctions.
A doctor may have opted in to email communication but never agreed to instant messaging or targeted digital ads. DPDP requires consent to cover the actual channel used.
Using opt in consent as a blanket permission across channels violates DPDP expectations.
This affects WhatsApp, email, SMS, and digital campaigns alike.
Learn how consent must be captured separately across channels in channel-specific consent collection.
Time Bound Nature of Consent
Opt in models often assume consent is permanent.
DPDP challenges this assumption. Consent must remain relevant to the stated purpose. If circumstances change, consent may no longer be valid. Individuals must also be able to withdraw consent at any time.
Opt in records captured years ago without renewal or revalidation are difficult to defend under DPDP.
Impact on Doctor Marketing Workflows
Doctor marketing workflows are particularly affected.
Legacy databases often contain opt in records with unclear provenance. Campaign automation relies on these records to trigger outreach. Consent validation is rarely part of execution logic.
Under DPDP, this creates a disconnect between compliance intent and operational reality.
Without a structured pharma consent governance solution, this disconnect increases compliance risk at scale.
This is why DPDP-compliant HCP marketing frameworks are becoming essential. They ensure consent is validated at the point of engagement rather than assumed.
Opt In Versus Explicit Consent in Practice
The difference between opt in and explicit consent becomes clear during audits.
Regulators ask how consent was obtained, what information was provided, and how consent governs actual data use. Opt in records that lack context or scope are weak evidence.
Explicit consent, when implemented properly, creates a defensible trail that aligns with DPDP requirements.
Impact on Patient Programs
Opt in models are even riskier in patient programs.
Patient data is often sensitive. Consent must clearly explain how data will be used, whether it will be shared, and how long it will be retained.
Generic opt in consent exposes organisations to higher scrutiny and potential harm.
CRM and System Limitations
Most CRMs were not designed to enforce DPDP level consent logic.
This is why many CRM systems fail to support DPDP compliance. Learn more in why pharma CRMs fail at consent tracking
They store consent as a static attribute. They do not map consent to purpose or channel. They do not block execution when consent is missing or withdrawn.
Relying on such systems while assuming opt in is sufficient creates a false sense of security.
Why Opt In Fails During DPDP Audits ?
Audits highlight the limitations of opt in.
These gaps directly reflect DPDP consent requirements in pharma, where organisations must demonstrate how consent governs actual data processing.
Teams struggle to demonstrate consent scope. Records lack clarity. Withdrawal processes are inconsistent.
DPDP expects evidence that consent governs actual processing, not just exists in theory.
Opt in models fail this test.
Redesigning Consent Beyond Opt In
Moving beyond opt in requires structural change.
This is where a consent management platform for pharma becomes essential to enforce consent dynamically across systems.
Consent capture must be redesigned to be explicit and purpose specific. Systems must enforce consent dynamically. Teams must be trained to treat consent as part of execution.
This transition takes effort, but it reduces long term risk.
Business Impact of Moving Beyond Opt In
While explicit consent may initially reduce addressable audience size, it improves engagement quality.
Doctors and patients who understand and control how their data is used are more likely to trust and engage. Over time, this leads to more sustainable marketing outcomes.
Closing Perspective and CTA
If your organisation is still relying on opt-in consent models, your compliance risk is increasing. Explore how a DPDP-compliant HCP marketing platform enables explicit, purpose-based consent enforcement across all engagement workflows.
Frequently Asked Questions on Opt In and DPDP
Because opt in often lacks purpose specificity, channel clarity, and auditability.
Yes. Consent must be explicit, informed, and purpose specific.
Only if they meet DPDP requirements, which many do not.
Only if consent clearly includes those channels.
The doctor, as the data principal, must provide consent.
Generic opt in is risky. Explicit consent is required.
CRMs must support consent enforcement at execution time.
Yes. Individuals can withdraw consent at any time.
Ready to Deploy AI in Your Pharma Operations?
Talk to our team about your HCP data, consent, or engagement challenges. No pitch — just a real conversation about what you need.
